Recruiting soon

Xuebijing Injection for Sepsis via PCDHAC2/BAX/AIM2 Pathway Regulation

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from today forward - Prospective
Who is being recruted

Infections+3

+ Inflammation

+ Pathologic Processes

From 18 to 75 Years
+8 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: March 2025
See protocol details

Summary

Principal SponsorSoutheast University, China
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: March 30, 2025

Actual date on which the first participant was enrolled.

Sepsis is a serious health condition where the body's response to an infection leads to organ dysfunction, often requiring intensive care. It poses a significant threat to human health. This study focuses on understanding how a treatment called hemopexin injection can help manage sepsis. Previous research has shown that this injection can significantly reduce the death rate within 28 days among sepsis patients. This study aims to clarify the specific target and molecular mechanism of hemopexin injection in treating sepsis, which could be crucial for developing precise treatments and new drugs for sepsis.

Official TitleXuebijing Injection Regulates Endothelial Cell Panapoptosis in Treating Sepsis Through PCDHAC2/BAX/AIM2 Pathway
NCT06920420
Principal SponsorSoutheast University, China
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

30 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 75 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

InfectionsInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsSystemic Inflammatory Response SyndromeSepsis

Criteria

3 inclusion criteria required to participate
Meeting the Sepsis 3.0 diagnostic criteria;
SOFA score ≥ 2 and < 13;
Signed informed consent.
5 exclusion criteria prevent from participating
Age <18 years or >75 years;
Pregnant or lactating women;
Presence of severe primary diseases including malignant tumors severe hematologic disorders and HIV infection;
Current use of immunosuppressants or history of organ transplantation within the past 6 months;
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available.
Recruiting soonNo study centers